Serum tumour markers in gynaecological cancers
Authors:
- Pakhee AggarwalPakhee Aggarwal
- Sean KehoeSKSean Kehoe
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Phase II biomarker trial of a multimarker diagnostic for ovarian cancerJournal of Cancer Research and Clinical Oncology, 2010
- Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cystsBritish Journal of Cancer, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusGynecologic Oncology, 2008
- Significance of elevated preoperative α-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumorsJournal of Surgical Oncology, 2006
- Worldwide burden of gynaecological cancer: The size of the problemBest Practice & Research Clinical Obstetrics & Gynaecology, 2006
- Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-BGynecologic Oncology, 2005
- Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal WomenJournal of Clinical Oncology, 2003
- Serum Inhibin and Disease Status in Women with Ovarian Granulosa Cell TumorsGynecologic Oncology, 1997
- VAB-6 Chemotherapy Causes Spurious Elevation of Alpha-Fetoprotein Associated with Liver DysfunctionsUrologia Internationalis, 1991